Cagrilintide
A long-acting amylin analog studied alongside GLP-1 agonists. Cagrilintide is researched for its complementary effects on appetite regulation and metabolic outcomes.
Compound Profile
Pharmaceutical Data Sheet
Mechanism of Action
How Cagrilintide Works
Cagrilintide is a long-acting analog of human amylin, a pancreatic hormone co-secreted with insulin that produces satiety. It activates amylin receptors (AMY1-3) in the area postrema and nucleus tractus solitarius to slow gastric emptying, reduce glucagon secretion, and suppress appetite centrally. When combined with semaglutide (CagriSema), the complementary amylin + GLP-1 mechanisms produce additive weight loss approaching bariatric surgery outcomes.
- Activates AMY1, AMY2, AMY3 receptor subtypes
- Area postrema and NTS satiety center activation
- Reduces meal size and total caloric intake dose-dependently
- Semaglutide component activates hypothalamic GLP-1R
- Dual mechanism produces 20.4% weight loss (vs. 3% placebo)
- 60% of CagriSema patients achieved >=20% weight loss
- Suppresses postprandial glucagon secretion
- Slows gastric emptying rate
- 88% of prediabetic patients returned to normoglycemia (REDEFINE 1)
Cagrilintide binds calcitonin and amylin receptors (CTR+RAMP1/2/3) in the brainstem area postrema, activating ascending satiety signals that reduce meal size and caloric intake. It slows gastric emptying and suppresses postprandial glucagon secretion. Its long acyl chain enables once-weekly dosing with sustained receptor occupancy. Phase 2 showed cagrilintide 4.5mg surpassed liraglutide 3.0mg (10.8% vs. 9.0%, P=0.03).
Lau DCW et al., Lancet (2021): Phase 2 dose-finding trial; Frias JP et al., N Engl J Med (2025): REDEFINE 1.
Preclinical Findings
Research Models
Clinical Data
REDEFINE 1: 20.4% Weight Loss at 68 Weeks — NEJM 2025
The REDEFINE 1 Phase 3a trial (N Engl J Med, 2025) demonstrated CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg) achieved -20.4% mean body weight vs. -3.0% placebo at 68 weeks (P<0.001). 60% achieved >=20% weight loss, 23% achieved >=30%. As monotherapy (separate Phase 2), cagrilintide 4.5mg produced 10.8% weight loss vs. 3.0% placebo, surpassing liraglutide 3.0mg (P=0.03). In REDEFINE 2 (T2D), CagriSema achieved -13.7% vs. -3.4% placebo.
Frias JP et al., N Engl J Med (2025): REDEFINE 1 & 2; Lau DCW et al., Lancet (2021): Phase 2.
Phase 3a RCTs (REDEFINE 1 & 2) published NEJM 2025; Phase 2 dose-finding (Lancet 2021)
Research Outcomes
Key Research Success Metrics
Safety Profile
Research Safety Notes
- Safety profile consistent with GLP-1 receptor agonist class — primarily GI adverse events
- Nausea is the most common AE (~55% CagriSema), generally transient and mild-to-moderate
- Low treatment discontinuation rates (6–8.4%) across REDEFINE Phase 3 trials
- No unexpected cardiovascular signals observed in Phase 3 program
- Long-term safety beyond 68 weeks under continued evaluation
Cagrilintide and CagriSema are investigational. REDEFINE Phase 3 data published in NEJM (2025). Not yet FDA-approved. For research use only.
About Cagrilintide
A long-acting amylin analog studied alongside GLP-1 agonists. Cagrilintide is researched for its complementary effects on appetite regulation and metabolic outcomes.
All EVO Labs Research compounds are manufactured to research-grade standards and independently tested by Janoshik Analytical (Prague, est. 2013). The Certificate of Analysis for this compound includes full HPLC chromatography data, mass spectrometry confirmation, net purity percentage, and net content verification.
Research Use Only
This product is strictly for in vitro research and laboratory use only. Not for human or veterinary consumption. By purchasing, you confirm use in a controlled research setting.
 10MG.png)
 10MG.png)
 10MG.png)
 5-PACK 10MG.png)